Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.

The changes reflect Mölnlycke’s continued focus on ensuring strong governance and relevant expertise as the company advances its growth journey and works to fulfil its purpose to revolutionise care for people and planet.
“We would like to thank Christian for his valuable contribution to the Mölnlycke Board and welcome Filippa and Thomas in their new roles,” said Karl-Henrik Sundström, Chairman of the Board. “Their experience and perspectives will support Mölnlycke as we continue to develop as a world-leading MedTech company.”
Filippa Stenberg currently serves as Managing Director of Patricia Industries, part of Investor AB, and brings extensive experience in active ownership and healthcare investments. She has served as deputy board member of Mölnlycke since 22 May 2025. Born in 1985, Filippa is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. Her board assignments include Swedish Orphan Biovitrum AB, Affibody Medical AB and Atlas Antibodies AB.
Thomas Kidane will join the Mölnlycke Board as deputy board member. Born in 1986, he is a Swedish citizen and holds an M.Sc. in Accounting and Financial Management from the Stockholm School of Economics. He is Co-Head of Patricia Industries, a member of Investor AB’s Executive Leadership Team, and serves on the boards of Permobil, Piab Group and Fortnox.
For more information, please contact:

Media Relations
Email: jamie.smith@molnlycke.com
Clinicians’ hands can receive up to 1,000 times more radiation than other parts of the body during image-guided procedures1; yet, radiation-attenuating gloves are used in only 10% of applicable cases2, putting healthcare professionals at risk of the damaging effects of radiation.
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
Mölnlycke Health Care has been honored with the Cardinal Health 2026 Rising Star Award, recognizing outstanding performance as a new member of the Cardinal Health Performance Plus Program.The award was presented during Cardinal Health's National Sales Meeting, held the week of August 9th, and reflects the strength of the partnership between the two organizations across Advanced Wound Care, Patient Positioning, and Antiseptics.
Peachtree Corners, GA. July 7, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.